---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-000265"
form_type: "8-K"
ticker: "PMI"
cik: "0002030617"
company_name: "Picard Medical, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:43:50.245958+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Picard Medical publishes investor presentation; expects FDA approval for fully implantable TAH by 2028

## Summary
- Over 2,100 STAH implants across 27 countries; only FDA-approved total artificial heart.
- Mid-term catalysts: updated BTC label (2Q26), MDR CE-mark (4Q26), NMPA approval (4Q26).
- Next-gen fully implantable TAH (Emperor) may seek FDA approval in 2028; patented.
- U.S. reimbursement under DRG001 (mean ~$297k); market cap ~$123M as of Jan 11, 2026.
- CEO Patrick Schnegelsberg leads team; stock traded $1.63-$13.68 since Aug 2025.

## SEC filing metadata
- accession: 0001829126-26-000265
- form_type: 8-K
- ticker: PMI
- cik: 0002030617
- company_name: Picard Medical, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030617/000182912626000265/0001829126-26-000265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030617/000182912626000265/picardmedical_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-000265
- JSON: https://secwatch.observer/filing/0001829126-26-000265.json
- Plain text: https://secwatch.observer/filing/0001829126-26-000265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.